Inside the cash-burning, uninsurable, and controversial plan to turn a pro-doping sporting event into a mainstream supplement empire.

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse...

It’s unclear if the pill Hims is selling works or if the FDA will allow it....

$10 billion of investment. Code names to disguise projects and companies. Mixed opinions. Skyrocketing property values. And enough tax breaks...

As people tire of swiping through hundreds of profiles, new VC-backed entrants as well as legacy apps are trying to shift toward quality over...

It’s hard to keep track of all the next-gen GLP-1s in the pipeline, but we tried our best....

The end of the partnership marks the latest schism drugmakers and telehealth providers....

The automotive veteran explains why her company can deliver a cheap electric vehicle when others, like Tesla, have failed....

From stoic Senator Bob Dole to racy ads targeting men on a gay dating app, erectile dysfunction marketing has changed wildly over the past three...

Cuts to Medicaid and signs that ACA enrollees are becoming costlier are weighing on some insurers. Is Centene the canary in the coal mine?...

Combination pills, like those that treat ED and hair loss at the same time, help companies like Hims & Hers and Ro with customer retention. But...

The company has high short interest and the stock has risen significantly in the past week. Its earnings report could be make or break for short...

Menlo Park, CA; New York, NY

The generic drug maker started with cheeky ads selling knockoff Viagra. Now it’s trying to fend off big drugmakers and navigate a critical government...

The news may have been fake but the market's desire for tariff relief is very, very real....

ALT: a man in a suit and tie playing a guitar

Laid-off government workers and Hegseth are leading the way....

In an unusual exchange, Green Thumb CEO Ben Kovler accused an ETF manager of influencing the price of his stock....

An accounting professor who studies trading by corporate insiders described the transactions as “very unusual.”...

How a puzzle designed to resist memorization is reshaping AI intelligence tests. See if you can score better than an AI model....

China is bad and the US is worse so far this year. Don’t even talk about Europe....

The world’s second-largest economy has been a prolonged pain point for one of Merck’s most important drugs....

It likely grew about 40% last year....